Cambridge Healthtech Institute’s 10th Annual

Kinase Inhibitor Chemistry
( 激酶抑制剂的化学 )


Over the past decade, kinase drug discovery has resulted in the rapid development of a new generation of anti-cancer drugs. As kinase inhibitor discovery remains an active area for a significant portion of all efforts, developers have found new ways to expand into a deeper portion of target space within the human kinome, moved beyond cancer and into chronic disease indications such as CNS disorders, as well as shifted toward allosteric modulation and harnessing slow-off or irreversible compounds. Cambridge Healthtech Institute’s 10th Annual Kinase Inhibitor Chemistry conference will once again bring together academic and industry leaders to network, collaborate and discuss advances in kinase discovery, design, screening and development.

Coverage will include, but is not limited to:


  • Tryosine kinase inhibitors
  • Covalent kinase inhibitors
  • Receptor interacting protein 1 (RIP1) kinase
  • Target covalent inhibitors
  • Macrocycle inhibitors
  • Reversible inhibitors
  • Residence time
  • Fragment and structure-based design
  • Lead & target optimization
  • Emerging kinase inhibitors for therapeutics indications: autoimmune diseases, CNS, neurodegenerative diseases, blood brain barrier issues, cancer
  • Case studies, clinical update and next generation of JAK, BTK, SYK
  • AK, MAPK, P13K and other kinases

* 活动内容有可能不事先告知作更动及调整。